Fact CheckerSign in

NCT07381101Completed

Trazodone and the Risk of Serious Adverse Events

Trazodone Dose and the Risk of Serious Adverse Events in Older Adults With Low Kidney Function: A Population-Based Cohort Study Research Protocol

Source: ClinicalTrials.gov · Last updated 5 Mar 2026

Brief summary (registry, in English)

This is a population-based retrospective, new-user, active comparator cohort study assessing whether initiating a new outpatient prescription of trazodone (\>75-150 mg/day), compared to a lower dose (25-75 mg/day) is associated with an increased 30-day risk of serious adverse events among older adults with low kidney function estimated glomerular filtration rate (eGFR) \<45 mL/min/1.73 m², who are not receiving dialysis and have no history of kidney transplantation. The primary outcome is a 30-day composite of all-cause hospitalization, all-cause emergency department visit, or all-cause mortality.

Status (registry)
Completed
Study type
Observational
Enrollment
31459 (actual)
First submitted
23 Jan 2026
Start date
1 Jan 2008
Primary completion date
1 Mar 2025
Lead sponsor
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
NCT number
NCT07381101

What you commit to

  • Study type: Observational
  • Participants enrolled: 31459
  • From 1 Jan 2008 to the primary completion date, 1 Mar 2025
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • Those with evidence of any study drug prescription 180 days before the index date (to restrict to new users only).
  • Individuals with more than one study drug prescription on the index date, as this complicates the ability to ascertain the prescribed dose accurately.
  • Individuals with end-stage renal disease, chronic dialysis, or a kidney transplant prior to the index date.
  • Evidence with hospital discharge or emergency department visit in the two days prior to or on the index date to ensure a new outpatient prescription.
  • Individuals receiving palliative care in the 0-365 days prior to the index date, in this setting, dosing is less relevant; rather, the focus is comfort care.
    • The investigators restrict to the first prescription in individuals with more than one eligible prescription. Date of this prescription will be the index date (the Date from which the outcomes start being assessed).

Lab values

  • Individuals with no serum creatinine lab value in the 0-365 days prior to the index date.
  • Individuals with unstable baseline kidney function:
    • If the most recent serum creatinine test prior to the index date was an inpatient test \[ER or hospitalization\] \<refer to this as test date 1\>, and there is not at least one 'outpatient' serum creatinine in the year before test date 1, OR If the most recent prior serum creatinine test prior to the index date was an inpatient test \[ER or hospitalization\] \<refer to this as test date 1\>, and while there is at least 'outpatient' serum creatinine test in the year before \<test date 1\>, the most recent outpatient test prior to \<test date 1\> differs by an eGFR 10 mL/min/1.73 m2 or more from the value on \<test date 1\>.
    • In Ontario, it has been shown that outpatient serum creatinine measurements in the province, conducted on a single occasion, indicate stable values.

Age

  • Individuals with missing administrative database number, missing or invalid age (\<0 or \>105 years), missing or invalid sex, death on or before the index date, non-Ontario resident (for Ontario data), or non-Alberta residents (for Alberta data).
  • Individuals less than 66 years of age on the index date.

Who the study is looking for

  • The cohort will will include all older adults (≥66 years) with an eGFR \<45 mL/min per 1.73 m2 (not receiving dialysis or having a history of kidney transplantation) who received a new outpatient prescription for oral trazodone with an initial dose between 25 and 150 mg/day and a day supply of ≥5 days between January 1, 2008 to March 1, 2025. The age criterion is set to guarantee that individuals in this population have had at least one year of prior prescription drug coverage. The date when the prescription was filled will serve as the patient's entry or index date for the cohort, with each patient entering the cohort only once.

Age in the registry: 66 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
London Health Sciences Centre Research Institute
Coordinator of this site? Confirm its status
LondonCanadaUnknown status

This page is information, not medical advice. Discuss any trial with your doctor.